增加被诊断患有乳腺癌的黑人妇女的临床试验参与率
Ricki Fairley1, James W Lillard2, Alexandra Berk3
1TOUCH, The Black Breast Cancer Alliance, Annapolis, MD, USA.
Journal of racial and ethnic health disparities
|June 14, 2023
概括
黑人女性,尽管对乳腺癌临床试验的认识,但仍然存在负面的看法,并面临参与障碍. 值得信赖的来源和积极的医疗保健提供者讨论对于明智的决策至关重要.
科学领域:
- 在瘤学瘤学.
- 健康差异 在健康上的差异
- 临床研究 临床研究
背景情况:
- 在乳腺癌死亡率方面,种族差异仍然存在.
- 黑人女性在临床试验中的代表性明显不足.
研究的目的:
- 探索患有乳腺癌的黑人女性的生活经历.
- 确定影响黑人妇女关于临床试验参与的决策的障碍和动机.
主要方法:
- 混合方法方法结合了重点小组,深度访谈和在线调查.
- 定性数据为对257名被诊断患有乳腺癌的黑人妇女进行定量调查的开发提供了信息.
主要成果:
- 大多数参与者都知道临床试验,并积极地看待它们,但仍然存在显著的负面看法 (副作用,缺乏真正的治疗,潜在的伤害).
- 主要障碍包括财务担忧,担心病情恶化,安慰剂和未经批准的治疗方法.
- 参与者比医疗保健提供者 (HCP) 更频繁地启动试验讨论,许多人仍然需要更多的风险/益处信息. 医疗人员和支持小组是最值得信赖的信息来源.
结论:
- 值得信赖的社区来源和主动的HCP参与对于教育黑人妇女关于临床试验至关重要.
- 解决负面看法和实际障碍对于改善黑人女性临床试验积累至关重要.
更多相关视频
00:04A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
Published on: September 20, 2019
10.7K
07:41Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases
Published on: May 17, 2019
9.0K
相关概念视频
Clinical Trials
6.9K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
6.9K
Clinical Trials: Overview
3.0K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
3.0K
Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Cancer Survival Analysis
402
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
402
Blinding
2.5K
Blinding is a commonly used method of not telling participants which treatment a subject is receiving. Blinding is a critical part of a randomized control trial or RCT. It reduces the bias that affects the results. In an RCT, blinding is used in the form of a placebo. A placebo effect occurs when untreated subjects falsely believe they have received the treatment and report improved symptoms. A placebo or a dummy treatment is administered to subjects to negate the bias caused by such an effect.
2.5K
